Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study
-
Published:2024
Issue:
Volume:39
Page:100801
-
ISSN:2468-2942
-
Container-title:Cancer Treatment and Research Communications
-
language:en
-
Short-container-title:Cancer Treatment and Research Communications
Author:
Bordet ConstanceORCID,
Zureik Mahmoud,
Zelmat Yoann,
Lafaurie Margaux,
Lapeyre-Mestre Maryse,
Sommet Agnès,
Mazieres Julien,
Despas FabienORCID
Reference39 articles.
1. Lung cancer;Maghfoor;Ann. Saudi. Med.,2005
2. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers;Chapman;Lung Cancer,2016
3. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management;Solassol;Biomolecules.,2019
4. Treatment of non-small cell lung cancer with EGFR-mutations;Yoneda;J. UOEH.,2019
5. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region;Conte;Fundam. Clin. Pharmacol.,2019